FOXO-targeting compounds

FOXO-targeting compounds has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Jan 12, 2026: “FOXO: a key target in regulating aging and age-related diseases”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on FOXO-targeting compounds

What did studies of FOXO-targeting compounds find?

1

Studies of FOXO-targeting compounds measured one outcome, metabolic disease.

Metabolic disease

downin reviews1

1 study
  1. FOXO-targeting compounds decrease metabolic disease.

    “These FOXO-targeting compounds demonstrate great potential in improving metabolic disorders and delaying the onset of aging phenotypes.”

    Review

    FOXO: a key target in regulating aging and age-related diseases

    Biogerontology

More on Metabolic disease

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months